Hanx Biopharmaceuticals Completes HK$586 Million Hong Kong IPO

Marco Zingaro Asia & Pacific Legal Chronicle
Tagged:

Ashurst has advised ICBC International Capital Limited. Hanx Biopharmaceuticals (Wuhan) Co., Ltd., a China-based biopharmaceutical company, has successfully completed a global offering amounting to HK$586.3 million,…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here